...
首页> 外文期刊>Cell Proliferation >In vitro effects of an in silico-modelled 17beta-estradiol derivative in combination with dichloroacetic acid on MCF-7 and MCF-12A cells.
【24h】

In vitro effects of an in silico-modelled 17beta-estradiol derivative in combination with dichloroacetic acid on MCF-7 and MCF-12A cells.

机译:计算机模拟的17β-雌二醇衍生物与二氯乙酸联合对MCF-7和MCF-12A细胞的体外作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVES: To investigate anti-proliferative properties of a novel in silico-modelled 17beta-oestradiol derivative (C9), in combination with dichloroacetic acid (DCA), on MCF-7 and MCF-12A cells. MATERIALS AND METHODS: xCELLigence system was employed to determine optimal seeding number for cells, and crystal violet assay was used to assess cell number and to determine IC(50) value (24 h) for combination treatment. Light and fluorescent microscopy techniques were used to morphologically detect types of cell death. Flow cytometry was used to analyse cell cycle and apoptosis. RESULTS: Optimal seeding number for 96-well plates was determined to be 5000-10 000 cells/well for both MCF-7 and MCF-12A cells. IC(50) for MCF-7 cells of the combination treatment after 24 h was 130 nm of C9 in conjunction with 7.5 mm of DCA (P < 0.05). In contrast, the same concentration inhibited cell population growth by only 29.3% for MCF-12As after 24-h treatment (P < 0.05). Morphological studies revealed lower cell density of both types of combination-treated cells. Flow cytometric analyses demonstrated increase in sub-G(1) phase in combination-treated MCF-7 cells. CONCLUSIONS: These results demonstrate that the novel 17beta-oestradiol derivative C9, in combination with DCA is a potent anti-proliferation treatment, with properties of selectivity towards tumourigenic cells. Thus, this warrants further studies as a potential combination chemotherapeutic agent for further cancer cell lines.
机译:目的:研究新型计算机模拟的17β-雌二醇衍生物(C9)与二氯乙酸(DCA)联合对MCF-7和MCF-12A细胞的抗增殖特性。材料与方法:xCELLigence系统用于确定细胞的最佳接种数,结晶紫测定法用于评估细胞数并确定IC(50)值(24小时)以进行联合处理。光和荧光显微镜技术用于形态检测细胞死亡的类型。流式细胞仪用于分析细胞周期和凋亡。结果:对于MCF-7和MCF-12A细胞,确定96孔板的最佳接种数为5000-10 000细胞/孔。 24小时后联合处理的MCF-7细胞的IC(50)为130 nm C9和7.5 mm DCA(P <0.05)。相反,相同浓度的MCF-12As在24小时治疗后仅能抑制29.3%的细胞群生长(P <0.05)。形态学研究显示,两种类型的联合处理细胞均具有较低的细胞密度。流式细胞仪分析表明联合治疗的MCF-7细胞在sub-G(1)期增加。结论:这些结果表明,新型的17β-雌二醇衍生物C9与DCA结合是一种有效的抗增殖治疗剂,对肿瘤细胞具有选择性。因此,作为进一步的癌细胞系的潜在组合化疗剂,这值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号